Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland

Karolina Hoffmann,1 Michał Michalak,2 Anna Paczkowska3 1Department and Clinic of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences, Poznań, Poland; 2Department of Computer Science and Statistics, Poznan University of Medical Sciences, Pozn...

Full description

Saved in:
Bibliographic Details
Main Authors: Hoffmann K, Michalak M, Paczkowska A
Format: Article
Language:English
Published: Dove Medical Press 2025-08-01
Series:Diabetes, Metabolic Syndrome and Obesity
Subjects:
GLP-1 receptor agonist
semaglutide
liraglutide
obesity
type 2 diabetes
Online Access:https://www.dovepress.com/relative-effectiveness-and-safety-of-the-glp-1-glucagon-like-peptide-1-peer-reviewed-fulltext-article-DMSO
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/relative-effectiveness-and-safety-of-the-glp-1-glucagon-like-peptide-1-peer-reviewed-fulltext-article-DMSO

Similar Items